Danish plans for national guidance on API audits criticised
This article was originally published in SRA
Plans by the Danish Medicines Agency to develop national guidelines that would assist drug companies in auditing sites manufacturing active pharmaceutical ingredients have come in for criticism from some quarters1.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.